Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O95436

UPID:
NPT2B_HUMAN

ALTERNATIVE NAMES:
Na(+)-dependent phosphate cotransporter 2B; NaPi3b; Sodium/phosphate cotransporter 2B; Solute carrier family 34 member 2

ALTERNATIVE UPACC:
O95436; A5PL17; Q8N2K2; Q8WYA9; Q9P0V7

BACKGROUND:
The Sodium-dependent phosphate transport protein 2B, known alternatively as NaPi3b, Sodium/phosphate cotransporter 2B, and part of the Solute carrier family 34 member 2, is integral to the cellular uptake of phosphate. This process is critical for numerous physiological functions, including the regulation of mineral and bone metabolism, as well as cellular energy transfer.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Pulmonary alveolar microlithiasis, a condition marked by the accumulation of calcium phosphate in the lungs, the Sodium-dependent phosphate transport protein 2B's dysfunction highlights its potential as a therapeutic target. Exploring the mechanisms by which this protein operates could unlock novel treatment avenues for individuals afflicted by this rare but severe respiratory disease.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.